Document is current

Article History

Received: 24 July 2024

Accepted: 6 February 2025

First Online: 5 March 2025

Declarations

:

: This matching-adjusted indirect comparison utilized data from clinical trials that were already completed. Both studies were performed in accordance with the Declaration of Helsinki, International Conference on Harmonization Good Clinical Practice guidelines, institutional review boards at participating institutions approved the study protocols and amendments, and all patients provided written informed consent.

: Not applicable.

: Bristol Myers Squibb contracted EVERSANA to complete this work. LJN discloses consultancy from Interius BioTherapeutics and SIRPant Immunotherapeutics; honoraria from ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, Daiichi Sankyo/UCB Japan, Epizyme, Genentech, Genmab, Gilead, Incyte, Ipsen, Janssen Oncology, MorphoSys, Novartis, Roche, Takeda, and TG Therapeutics; research funding from Allogene Therapeutics, Bristol Myers Squibb, Caribou Biosciences, Daiichi Sankyo/UCB Japan, Epizyme, Genentech, Genmab, Gilead, IgM Biosciences, Ipsen, Janssen Biotech, Novartis, and Takeda; and travel from Genentech/Roche. AB, PW, and LA are employees of EVERSANA. TF and JK are employees of Bristol Myers Squibb and may own stock. JD was an employee of Bristol Myers Squibb at the time the research was conducted. SD has no competing interests to declare.